Cocrystal Pharma, Inc. (NASDAQ:COCP)
| Market Cap | 19.26M-1.0% |
| Revenue (ttm) | 330.00K |
| Net Income | -9.94M+20.9% |
| EPS | -0.80+35.5% |
| Shares Out | 19.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50,514 |
| Open | 1.00 |
| Previous Close | 1.01 |
| Day's Range | 1.00 - 1.04 |
| 52-Week Range | 0.76 - 2.03 |
| Beta | 1.60 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About COCP
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Latest investor presentation
Next catalysts
- Nov 13, 2026Earnings report
Ask Barron about COCP
$COCP stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in COCP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by COCP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
COCP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
COCP Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Grant income | $498.00K | 62.96% |
| Stock-based compensation | $176.00K | 22.25% |
| Insurance | $117.00K | 14.79% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New COCP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to COCP from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in COCP
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $215.36K |
| VXFVanguard Extended Market ETF | $196.61K |
Estimated from each fund’s disclosed top holdings × AUM
COCP Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from COCP’s recent data — informational, not investment advice